Stepwise, precision-based management of allergic Bronchopulmonary Aspergillosis/Mycosis A real-life multicenter study
Main Article Content
Keywords
allergic brochopilmonary aspergilliosis (ABPA), allergic brochopulmonary mycosis (ABPM), antifungal therapy, omalizamub, systematic corticosteroids
Abstract
Background: Allergic bronchopulmonary aspergillosis (ABPA) and allergic bronchopulmonary mycosis (ABPM) are hypersensitivity disorders characterized by fungal colonization of the airways and exaggerated Th2-mediated immune responses. Despite corticosteroids being the cornerstone of treatment, adverse effects, relapses, and steroid dependence necessitate
adjunctive antifungal and biologic therapies. This study aimed to evaluate clinical, functional, and immunologic responses to different treatment combinations in patients with ABPA or ABPM.
Methods: This retrospective, multicenter, cross-sectional study included 70 patients diagnosed with ABPA (n = 54) or ABPM (n = 16) at two tertiary chest disease centers between 2016 and 2023. Patients were grouped according to systemic corticosteroid (SS) use (SS-using vs non-SS) and further subdivided based on treatment composition (antifungal ± biologic therapy vs antifungal alone). Changes in FEV1 (Forced Expiratory Volume in 1 second), Asthma Control Test (ACT) scores, total serum IgE, and peripheral blood eosinophil count (PBEC) before and after treatment were analyzed.
Results: In the SS-using group, combination therapy with antifungal ± biologic agents produced significant improvements in FEV1 (mL and %) and ACT scores, along with substantial reductions in total IgE and PBEC levels (all P < 0.05). Antifungal monotherapy yielded significant reductions in immunologic parameters but no functional improvement. In the non-SS group, changes were minimal across most parameters, except for a modest reduction in total IgE within the antifungal ± biologic subgroup. The most comprehensive clinical and immunologic responses were observed in patients treated with corticosteroids combined with antifungal and biologic therapy.
Conclusion: SS remain the primary therapeutic modality for ABPA, but the addition of antifungal and biologic agents enhances both immunologic and functional recovery. A precision-based, stepwise treatment model—initiating with corticosteroids, followed by antifungal therapy, and incorporating targeted biologics—may optimize long-term outcomes, minimize steroid exposure, and promote sustained remission in ABPA and ABPM.
References
2. Cosme J, Pedro E, Pereira-Santos MC, Lopes A, Caiado J, Paulino M, et al. [A3.1][A3.2]Molecular sensitization profile to grass and olive pollens in Portugal. Eur Ann Allergy Clin Immunol. 2024 Jun 24. Online ahead of print. https://doi.org/10.23822/EurAnnACI.1764-1489.347
3. Dramburg S, Hilger C, Santos AF, de las Vecillas L, Aalberse RC, Acevedo N, et al. EAACI Molecular Allergology User’s Guide 2.0. Pediatr Allergy Immunol. 2023; 34(Suppl 28): e13854. https://doi.org/10.1111/pai.13854.
4. Miller, Jeffrey D. The role of dust mites in allergy. Clin Rev Allergy Immunol. 2019;57(3):312–29. https://doi.org/10.1007/s12016-018-8693-0
5. Acevedo N, Josefina Z, Luis C. House dust mite allergy under changing environments. Allergy Asthma Immunol Res. 2019;11(4):450–69. https://doi.org/10.4168/aair.2019.11.4.450
6. Adgate JL, Zenge JP, Eggleston PA, Stout JW, Home EL, Rusznak C, et al. Allergen levels in inner city homes: Baseline concentrations and evaluation of intervention effectiveness. J Expo Sci Environ Epidemiol. 2008;18(4):430–440. https://doi.org/10.1038/sj.jes.7500638
7. Kaya MA, Koçacık Uygun DF, Celik E, Bingöl A, Azkur D, Ozturk AB, et al. The role of climate and residency in storage mite sensitivity among children with allergic diseases in the Mediterranean region. Int Arch Allergy Immunol. 2025 ;186(1):1–16. https://doi.org/10.1159/000543530
8. Caraballo L, Acevedo N, Ansotegui IJ, Ebisawa M, Kalogeromitros D, Kahriman F, et al. Blomia tropicalis: A 50-year history. J Allergy Clin Immunol Pract. 2024. Online ahead of print. https://doi.org/10.1016/j.jaip.2024.11.007
9. Lima DCA, Silva AF, Mendes L, Ferreira J, Costa R, Soares A, et al. A multi-variable constrained ensemble of regional climate projections under multi-scenarios for Portugal—Part II: Sectoral climate indices. Climate Ser. 2023; 30:100377. https://doi.org/10.1016/j.cliser.2023.100377
10. Peixoto J. Back to the south: Social and political aspects of Latin American migration to Southern Europe. Int Migration. 2012;50(6):58–82. https://doi.org/10.1111/j.1468-2435.2009.00537.x
11. Daschner Á, García Rodríguez R, Fernández-Nieto M, Pérez Frías MT, Rodríguez-González A, Sanz ML, et al. Imported subclinical house dust mite sensitisation in migrants from geohelminth endemic developing countries. Allergol Immunopathol (Madr). 2009;37(3):165–167. https://doi.org/10.1016/S0301-0546(09)71729-X
12. Lindqvist M, Leth-Møller KB, Linneberg A, Kull I, Bergström A, Georgellis A, et al. Natural course of pollen-induced allergic rhinitis from childhood to adulthood: A 20-year follow-up. Allergy. 2024;79(4):884–893.https://doi.org/10.1111/all.15927
13. Gouveia C, DaCamara CC. Land cover map for Portugal using VEGETATION data. In: Proceedings of the 31st International Symposium on Remote Sensing of Environment (ISRSE 2005): Global Monitoring for Sustainability and Security; 2005 Jun 20-24; St. Petersburg, Russian Federation.
14. Camacho I, et al. Airborne pollen calendar of Portugal: A 15-year survey (2002–2017). Allergol Immunopathol. 2020;48(2):194–201. https://doi.org/10.1016/j.aller.2019.06.012
15. Elisyutina O, et al. Bet v 1-specific IgE levels and PR-10 reactivity discriminate silent sensitization from phenotypes of birch allergy. Allergy. 2019;74(12):2525. https://doi.org/10.1111/all.13931
